ORYZON to outline development of Lysine Specific Demethylase Inhibitors for Oncological and Neurodegenerative Diseases at Keystone ...
BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - January 30, 2017) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical …